<DOC>
	<DOCNO>NCT00507858</DOCNO>
	<brief_summary>Primary Objective : - To determine maximum tolerated dos ( MTDs ) pemetrexed give dexamethasone . ( Please note : One three treatment group receive dexamethasone ) Secondary Objectives : - To assess dose limit toxicity ( DLT ) , define grade 4 neutropenia &gt; 7 day duration , neutropenic fever , grade 4 thrombocytopenia , grade 3 4 non-hematologic toxicity exclude nausea/vomiting exclude grade 3 transaminase toxicity . - To determine objective response rate , define complete response ( CR ) partial response ( PR ) , confirm 2 CT scan least 6 week apart patient treat pemetrexed single agent advance squamous cell carcinoma head neck .</brief_summary>
	<brief_title>Pemetrexed ( Alimta ) Patients With Head Neck Squamous Cell Cancer</brief_title>
	<detailed_description>Pemetrexed design block enzyme body important tumor growth . If find eligible take part study , assign one 3 group . All participant receive pemetrexed every 3 week needle vein 10 minute . Every 3 week consider 1 cycle . Participants Group 1 receive pemetrexed . Participants Group 2 also receive dexamethasone Day 1 cycle needle vein . Participants Group 3 take dexamethasone mouth day , day , day receive pemetrexed . Three ( 3 ) different dose level pemetrexed study . The first group 6 participant treat Dose Level 1 ( low 3 dos ) evaluate 3 week . If 0 1 6 participant experience severe side effect Dose Level 1 , next group 6 participant treat Dose Level 2 . At give dose , great 1 6 participant experience severe side effect , participant receive dose high dose . Every 3 week ( cycle ) , physical exam , include measurement vital sign ( temperature , pulse , breathe rate , blood pressure ) weight . Blood ( 3-4 teaspoon ) collect routine test . A performance status evaluation ( test look ability perform everyday activity ) liver function test also do . Your tumor evaluate CT scan chest x-ray every 2 cycle study treatment . While study , require take folic acid mouth every day 5-7 day first dose pemetrexed continue 3 week last dose pemetrexed . You also receive injection vitamin B12 muscle 1 2 week first dose pemetrexed . The vitamin B12 injection repeat every 9 week 3 week last dose pemetrexed . It important folic acid vitamin B12 give decrease risk severe side effect pemetrexed . You may receive 6 cycle treatment . You take study disease get bad intolerable side effect occur . When stop taking study drug study , physical exam , include measurement vital sign ( temperature , pulse , breathe rate , blood pressure ) weight . Blood ( 3-4 teaspoon ) collect routine test . A performance status evaluation ( test look ability perform everyday activity ) liver function test ( 1-2 teaspoon blood ) also do . After completion 6 cycle treatment , ask return clinic follow-up visit every 2-3 month standard follow-up . This investigational study . The FDA approve pemetrexed treatment non-small cell lung cancer . However , FDA authorize pemetrexed research patient HNSCC . Between 40-50 patient take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Squamous Cell</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>1 . Patients must histologically cytologically confirm metastatic recurrent head neck squamous cell carcinoma primary lesion and/or lymph node oral cavity , oropharynx , hypopharynx , larynx . 2 . Patients must measurable disease , define least one lesion accurately measure least one dimension ( long diameter record ) &gt; /= 20 mm conventional technique &gt; /= 10 mm spiral CT scan . 3 . Patients receive one chemotherapy regimens . 4 . Age &gt; /= 18 year . 5 . Life expectancy great 3 month . 6 . No acute intercurrent illness infection . 7 . ECOG performance status &lt; /= 2 ( Karnofsky &gt; /= 60 % ) 8 . Laboratory parameter : white blood count ( WBC ) &gt; 3,000/mL ; Neutrophils &gt; 1,500/mL ; Hemoglobin &gt; 8g/dL ; Platelets &gt; 100,000/mL ; Bilirubin &lt; 1.5 time upper limit normal ( ULN ) ; Serum creatinine : within normal institutional limit ; aspartate aminotransferase ( AST SGOT ) alanine aminotransferase ( ALT SGPT ) &lt; 3 time institutional ULN alkaline phosphatase &lt; ULN , except know hepatic metastasis , wherein ALT/AST may &lt; /= 5 time ULN 9 . Creatinine clearance : The standard Cockcroft Gault formula measure glomerular filtration rate ( GFR ) use appropriate radiolabeled method ( 51CrEDTA Tc99mDTPA ) must use calculate CrCl enrollment dosing . The method use baseline use throughout study . No dosage adjustment need patient CrCl &gt; /= 45 mL/min . 10 . Patients history nonmelanoma skin cancer , malignancy treat 5 year prior current tumor , patient remain continually diseasefree , eligible . 11 . Ability understand willingness sign write informed consent document . 1 . Acute intercurrent illness infection 2 . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement 3 . Patients receive investigational agent 4 . Patients know brain metastasis 5 . Patients sign symptom acute infection require systemic therapy . 6 . Patients history nonmelanoma skin cancer , malignancy , treat less 5 year prior current tumor 7 . Patients require total parental nutrition lipid . 8 . Patients exhibit confusion , disorientation , history major psychiatric illness may impair understand informed consent . 9 . Patients refuse sign inform consent . 10 . Histology squamous cell carcinoma . 11 . Inability unwillingness take folic acid vitamin B12 supplementation 12 . Inability take corticosteroid 13 . Inability interrupt aspirin nonsteroidal antiinflammatory agent 5day period ( shortacting NSAIDs ) 8day period ( longacting NSAIDs , piroxicam ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Head Neck Cancer</keyword>
	<keyword>Squamous Cell Cancer</keyword>
	<keyword>Alimta</keyword>
	<keyword>Pemetrexed</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>HNSCC</keyword>
	<keyword>Decadron</keyword>
</DOC>